News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Novo Nordisk A/S (NVO) Shares Drop on U.S. Scrutiny of Insulin Drug


10/26/2012 6:09:02 AM

Novo Nordisk A/S | Jobs at Novo Nordisk A/S

Shares in Denmark's Novo Nordisk fell as much as 5 percent on Friday, after a U.S. expert panel assessing the group's ultra long-acting insulin degludec said it will study the cardiovascular safety of the drug.

The statement late on Thursday raised a potential obstacle to approval of the drug, which Novo plans to market under the brand name Tresiba, in the world's top market ahead of the panel's meeting on November 8.

Read at News Release
Read at Reuters
Read at Bloomberg
Read at Fox News

comments powered by Disqus
   
Diabetes

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES